{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:19Z","timestamp":1792782499898,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001692","name":"Croucher Foundation","doi-asserted-by":"publisher","award":["Croucher Foundation Senior Medical Research Fellow"],"award-info":[{"award-number":["Croucher Foundation Senior Medical Research Fellow"]}],"id":[{"id":"10.13039\/501100001692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["Research Impact Fund (CU R4012-18)"],"award-info":[{"award-number":["Research Impact Fund (CU R4012-18)"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["Theme-based Research Scheme (T12-402\/13N)"],"award-info":[{"award-number":["Theme-based Research Scheme (T12-402\/13N)"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["University Research Grants Matching Scheme"],"award-info":[{"award-number":["University Research Grants Matching Scheme"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["Focused Innovation Scheme"],"award-info":[{"award-number":["Focused Innovation Scheme"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Diagnostis (Hong Kong) Limited","award":["An investigator-initiated grant (to RCWM)"],"award-info":[{"award-number":["An investigator-initiated grant (to RCWM)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>N-terminal pro B-type natriuretic peptide (NT-proBNP) is a natriuretic peptide that is strongly associated with congestive heart failure (CHF). The utility of NT-proBNP for prediction of cardiovascular events and renal endpoints, compared with clinical risk factors, has not been evaluated in detail. We hypothesise that NT-proBNP can improve risk stratification and prediction of cardiorenal events in type 2 diabetes, beyond that provided by clinical risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NT-proBNP was measured in 1993 samples from the Hong Kong Diabetes Biobank, a multicentre prospective diabetes cohort and biobank. A cut-off of \u2265125 pg\/ml was used to define elevated NT-proBNP. Associations between elevated NT-proBNP and incident cardiovascular and renal endpoints were examined using Cox regression, adjusted for sex, age and duration of diabetes, as well as other covariates. Prognostic and incremental predictive values of NT-proBNP in diabetes cardiorenal complications, compared with those of the Joint Asia Diabetes Evaluation risk equations for CHD, CHF and kidney failure, were evaluated using the concordance index (C index), net reclassification improvement index, integrated discrimination improvement index and relative integrated discrimination improvement index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 24.7% of participants had elevated NT-proBNP. Participants with elevated NT-proBNP at baseline had a more adverse cardiometabolic profile, with 2\u20134-fold higher frequency of complications at baseline. Adjusting for age at baseline, sex and duration of diabetes, elevated NT-proBNP was associated with incident atrial fibrillation (HR 4.64 [95% CI 2.44, 8.85]), CHD (HR 4.21 [2.46, 7.21]), CVD (HR 3.32 [2.20, 5.01]) and CHF (HR 4.18 [2.18, 8.03]; all\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). All these associations remained significant after further adjustment for additional covariates. Elevated NT-proBNP had good discriminative ability for various cardiorenal endpoints, with C index of 0.83 (95% CI 0.76, 0.90) for CHD, 0.88 (0.81, 0.94) for atrial fibrillation, 0.89 (0.83, 0.95) for CHF, 0.81 (0.77, 0.84) for 40% drop in eGFR and 0.88 (0.84, 0.92) for kidney failure. Models incorporating NT-proBNP had improved prediction compared with established clinical risk models. Sensitivity analyses including alternative cut-off of NT-proBNP, as well as use of other risk engines of CHD, yielded similar results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>NT-proBNP demonstrated a promising ability to serve as a prognostic marker for a variety of cardiorenal complications in type 2 diabetes. Considering NT-proBNP in clinical assessments could potentially help identify high-risk individuals who may benefit from more intensive therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-024-06299-x","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:06:39Z","timestamp":1730952399000},"page":"342-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes Biobank"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-803X","authenticated-orcid":false,"given":"Ronald C. W.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-0013","authenticated-orcid":false,"given":"Claudia H. T.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S. H.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-0560","authenticated-orcid":false,"given":"Risa","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-1286","authenticated-orcid":false,"given":"Juliana N. M.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-3387","authenticated-orcid":false,"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-6764","authenticated-orcid":false,"given":"Alice P. S.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-4760","authenticated-orcid":false,"given":"Chuiguo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C. W.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-9467","authenticated-orcid":false,"given":"Erik G.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-6069","authenticated-orcid":false,"given":"Andrea O. Y.","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-7402","authenticated-orcid":false,"given":"Wing Yee","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-9199","authenticated-orcid":false,"given":"Cadmon K. P.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1194","authenticated-orcid":false,"given":"Juliana C. N.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Hong Kong Diabetes Biobank Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"5","key":"6299_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 102(5):974\u2013989. https:\/\/doi.org\/10.1016\/j.kint.2022.08.012","journal-title":"Kidney Int"},{"issue":"12","key":"6299_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925\u20131966. https:\/\/doi.org\/10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"issue":"1","key":"6299_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s43856-023-00429-z","volume":"4","author":"A Ahmad","year":"2024","unstructured":"Ahmad A, Lim LL, Morieri ML et al (2024) Precision prognostics for cardiovascular disease in type 2 diabetes: a systematic review and meta-analysis. Commun Med (Lond) 4(1):11. https:\/\/doi.org\/10.1038\/s43856-023-00429-z","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"6299_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s43856-023-00359-w","volume":"3","author":"KG Young","year":"2023","unstructured":"Young KG, McInnes EH, Massey RJ et al (2023) Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. Commun Med (Lond) 3(1):131. https:\/\/doi.org\/10.1038\/s43856-023-00359-w","journal-title":"Commun Med (Lond)"},{"issue":"12","key":"6299_CR5","doi-asserted-by":"publisher","first-page":"e873","DOI":"10.1016\/S2589-7500(22)00174-1","volume":"4","author":"JM Dennis","year":"2022","unstructured":"Dennis JM, Young KG, McGovern AP et al (2022) Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health 4(12):e873\u2013e883. https:\/\/doi.org\/10.1016\/S2589-7500(22)00174-1","journal-title":"Lancet Digit Health"},{"issue":"7","key":"6299_CR6","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2337\/dci20-0022","volume":"43","author":"WK Chung","year":"2020","unstructured":"Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43(7):1617\u20131635. https:\/\/doi.org\/10.2337\/dci20-0022","journal-title":"Diabetes Care"},{"issue":"10","key":"6299_CR7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","volume":"29","author":"DK Tobias","year":"2023","unstructured":"Tobias DK, Merino J, Ahmad A et al (2023) Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med 29(10):2438\u20132457. https:\/\/doi.org\/10.1038\/s41591-023-02502-5","journal-title":"Nat Med"},{"issue":"6","key":"6299_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/cs1010671","volume":"101","author":"RJ Stevens","year":"2001","unstructured":"Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101(6):671\u2013679. https:\/\/doi.org\/10.1042\/cs1010671","journal-title":"Clin Sci (Lond)"},{"issue":"9","key":"6299_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera AV, Chaffin M, Aragam KG et al (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50(9):1219\u20131224. https:\/\/doi.org\/10.1038\/s41588-018-0183-z","journal-title":"Nat Genet"},{"issue":"1","key":"6299_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13073-021-00831-z","volume":"13","author":"CHT Tam","year":"2021","unstructured":"Tam CHT, Lim CKP, Luk AOY et al (2021) Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians. Genome Med 13(1):29. https:\/\/doi.org\/10.1186\/s13073-021-00831-z","journal-title":"Genome Med"},{"issue":"11","key":"6299_CR11","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.2337\/dc18-0709","volume":"41","author":"ML Morieri","year":"2018","unstructured":"Morieri ML, Gao H, Pigeyre M et al (2018) Genetic tools for coronary risk assessment in type 2 diabetes: a cohort study from the ACCORD clinical trial. Diabetes Care 41(11):2404\u20132413. https:\/\/doi.org\/10.2337\/dc18-0709","journal-title":"Diabetes Care"},{"issue":"2","key":"6299_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.ajkd.2021.11.011","volume":"80","author":"Q Jin","year":"2022","unstructured":"Jin Q, Luk AO, Lau ESH et al (2022) Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes: findings from the Hong Kong Diabetes Biobank. Am J Kidney Dis 80(2):196-206 e191. https:\/\/doi.org\/10.1053\/j.ajkd.2021.11.011","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"6299_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","volume":"21","author":"C Mueller","year":"2019","unstructured":"Mueller C, McDonald K, de Boer RA et al (2019) Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 21(6):715\u2013731. https:\/\/doi.org\/10.1002\/ejhf.1494","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"6299_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cardfail.2023.02.009","volume":"29","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS et al (2023) Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the heart failure association of the European society of cardiology, heart failure society of America and Japanese Heart Failure Society. J Card Fail 29(5):787\u2013804. https:\/\/doi.org\/10.1016\/j.cardfail.2023.02.009","journal-title":"J Card Fail"},{"issue":"5","key":"6299_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jchf.2019.12.010","volume":"8","author":"NE Ibrahim","year":"2020","unstructured":"Ibrahim NE, Burnett JC Jr, Butler J et al (2020) Natriuretic peptides as inclusion criteria in clinical trials: a JACC: heart failure position paper. JACC Heart Fail 8(5):347\u2013358. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.010","journal-title":"JACC Heart Fail"},{"issue":"6","key":"6299_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.kint.2019.07.025","volume":"96","author":"M Kammer","year":"2019","unstructured":"Kammer M, Heinzel A, Willency JA et al (2019) Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int 96(6):1381\u20131388. https:\/\/doi.org\/10.1016\/j.kint.2019.07.025","journal-title":"Kidney Int"},{"issue":"11","key":"6299_CR17","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.2337\/dci19-0003","volume":"42","author":"JCN Chan","year":"2019","unstructured":"Chan JCN, Lim LL, Luk AOY et al (2019) From Hong Kong diabetes register to JADE program to RAMP-DM for data-driven actions. Diabetes care 42(11):2022\u20132031. https:\/\/doi.org\/10.2337\/dci19-0003","journal-title":"Diabetes care"},{"issue":"7","key":"6299_CR18","doi-asserted-by":"publisher","first-page":"e1003209","DOI":"10.1371\/journal.pmed.1003209","volume":"17","author":"G Jiang","year":"2020","unstructured":"Jiang G, Luk AO, Tam CHT et al (2020) Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: a cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. PLoS Med 17(7):e1003209. https:\/\/doi.org\/10.1371\/journal.pmed.1003209","journal-title":"PLoS Med"},{"issue":"3","key":"6299_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2337\/db21-0694","volume":"71","author":"G Jiang","year":"2022","unstructured":"Jiang G, Luk AO, Tam CHT et al (2022) Clinical predictors and long-term impact of acute kidney injury on progression of diabetic kidney disease in Chinese patients with type 2 diabetes. Diabetes 71(3):520\u2013529. https:\/\/doi.org\/10.2337\/db21-0694","journal-title":"Diabetes"},{"issue":"4","key":"6299_CR20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1464-5491.1993.tb00083.x","volume":"10","author":"K Piwernetz","year":"1993","unstructured":"Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M (1993) Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med 10(4):371\u2013377. https:\/\/doi.org\/10.1111\/j.1464-5491.1993.tb00083.x","journal-title":"Diabet Med"},{"issue":"9","key":"6299_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"18","key":"6299_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1093\/eurheartj\/ehn334","volume":"29","author":"M Huelsmann","year":"2008","unstructured":"Huelsmann M, Neuhold S, Strunk G et al (2008) NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 29(18):2259\u20132264. https:\/\/doi.org\/10.1093\/eurheartj\/ehn334","journal-title":"Eur Heart J"},{"issue":"36","key":"6299_CR23","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"1","key":"6299_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ehf2.14149","volume":"10","author":"S Aoki","year":"2023","unstructured":"Aoki S, Yamagishi K, Kihara T et al (2023) Risk factors for pre-heart failure or symptomatic heart failure based on NT-proBNP. ESC Heart Fail 10(1):90\u201399. https:\/\/doi.org\/10.1002\/ehf2.14149","journal-title":"ESC Heart Fail"},{"issue":"3","key":"6299_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/dmrr.675","volume":"23","author":"X Yang","year":"2006","unstructured":"Yang X, Kong AP, So WY et al (2006) Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. Diabetes Metab Res Rev 23(3):220\u2013226. https:\/\/doi.org\/10.1002\/dmrr.675","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"6299_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjcard.2007.10.019","volume":"101","author":"X Yang","year":"2008","unstructured":"Yang X, So WY, Kong AP et al (2008) Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 101(5):596\u2013601. https:\/\/doi.org\/10.1016\/j.amjcard.2007.10.019","journal-title":"Am J Cardiol"},{"issue":"10","key":"6299_CR27","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00125-006-0376-3","volume":"49","author":"XL Yang","year":"2006","unstructured":"Yang XL, So WY, Kong AP et al (2006) End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 49(10):2299\u20132308. https:\/\/doi.org\/10.1007\/s00125-006-0376-3","journal-title":"Diabetologia"},{"issue":"6","key":"6299_CR28","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s00125-007-0639-7","volume":"50","author":"XL Yang","year":"2007","unstructured":"Yang XL, So WY, Kong AP et al (2007) Modified end-stage renal disease risk score for Chinese type 2 diabetic patients\u2014the Hong Kong Diabetes Registry. Diabetologia 50(6):1348\u20131350. https:\/\/doi.org\/10.1007\/s00125-007-0639-7","journal-title":"Diabetologia"},{"issue":"9","key":"6299_CR29","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM (2013) UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56(9):1925\u20131933. https:\/\/doi.org\/10.1007\/s00125-013-2940-y","journal-title":"Diabetologia"},{"issue":"3","key":"6299_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2337\/dc17-2002","volume":"41","author":"S Basu","year":"2018","unstructured":"Basu S, Sussman JB, Berkowitz SA et al (2018) Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) using individual participant data from diverse longitudinal cohorts in the U.S. Diabetes Care 41(3):586\u2013595. https:\/\/doi.org\/10.2337\/dc17-2002","journal-title":"Diabetes Care"},{"issue":"37","key":"6299_CR31","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M et al (2023) 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"issue":"17","key":"6299_CR32","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"6299_CR33","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","volume":"76","author":"JL Januzzi Jr","year":"2020","unstructured":"Januzzi JL Jr, Xu J, Li J et al (2020) Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction. J Am Coll Cardiol 76(18):2076\u20132085. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.004","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"6299_CR34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","volume":"4","author":"P Willeit","year":"2016","unstructured":"Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S et al (2016) Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol 4(10):840\u2013849. https:\/\/doi.org\/10.1016\/S2213-8587(16)30196-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"6299_CR35","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.2073","volume":"23","author":"TA Zelniker","year":"2021","unstructured":"Zelniker TA, Morrow DA, Mosenzon O et al (2021) Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail 23(6):1026\u20131036. https:\/\/doi.org\/10.1002\/ejhf.2073","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"6299_CR36","doi-asserted-by":"publisher","first-page":"e017462","DOI":"10.1161\/JAHA.120.017462","volume":"9","author":"MVB Malachias","year":"2020","unstructured":"Malachias MVB, Jhund PS, Claggett BL et al (2020) NT-proBNP by itself predicts death and cardiovascular events in high-risk patients with type 2 diabetes mellitus. J Am Heart Assoc 9(19):e017462. https:\/\/doi.org\/10.1161\/JAHA.120.017462","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"6299_CR37","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.amjmed.2017.08.003","volume":"130","author":"KW Chang","year":"2017","unstructured":"Chang KW, Hsu JC, Toomu A, Fox S, Maisel AS (2017) Clinical applications of biomarkers in atrial fibrillation. Am J Med 130(12):1351\u20131357. https:\/\/doi.org\/10.1016\/j.amjmed.2017.08.003","journal-title":"Am J Med"},{"issue":"18","key":"6299_CR38","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","volume":"120","author":"KK Patton","year":"2009","unstructured":"Patton KK, Ellinor PT, Heckbert SR et al (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 120(18):1768\u20131774. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.873265","journal-title":"Circulation"},{"issue":"2","key":"6299_CR39","doi-asserted-by":"publisher","first-page":"e007607","DOI":"10.1161\/CIRCEP.119.007607","volume":"13","author":"L Staerk","year":"2020","unstructured":"Staerk L, Preis SR, Lin H et al (2020) Protein biomarkers and risk of atrial fibrillation: the FHS. Circ Arrhythm Electrophysiol 13(2):e007607. https:\/\/doi.org\/10.1161\/CIRCEP.119.007607","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"6299_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ehf2.13703","volume":"9","author":"SM Werhahn","year":"2022","unstructured":"Werhahn SM, Becker C, Mende M et al (2022) NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Fail 9(1):100\u2013109. https:\/\/doi.org\/10.1002\/ehf2.13703","journal-title":"ESC Heart Fail"},{"issue":"5","key":"6299_CR41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1053\/j.ajkd.2011.05.020","volume":"58","author":"AS Desai","year":"2011","unstructured":"Desai AS, Toto R, Jarolim P et al (2011) Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 58(5):717\u2013728. https:\/\/doi.org\/10.1053\/j.ajkd.2011.05.020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6299_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J et al (2020) Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 75(1):84\u2013104. https:\/\/doi.org\/10.1053\/j.ajkd.2019.06.009","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6299_CR43","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12933-022-01726-y","volume":"21","author":"Q Jin","year":"2022","unstructured":"Jin Q, Lau ESH, Luk AO et al (2022) High-density lipoprotein subclasses and cardiovascular disease and mortality in type 2 diabetes: analysis from the Hong Kong Diabetes Biobank. Cardiovasc Diabetol 21(1):293. https:\/\/doi.org\/10.1186\/s12933-022-01726-y","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"6299_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00125-024-06108-5","volume":"67","author":"Q Jin","year":"2024","unstructured":"Jin Q, Lau ESH, Luk AO et al (2024) Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank. Diabetologia 67(5):837\u2013849. https:\/\/doi.org\/10.1007\/s00125-024-06108-5","journal-title":"Diabetologia"},{"issue":"1","key":"6299_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12933-017-0507-9","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Albiero M, Zaninotto M, Plebani M, Avogaro A (2017) DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. Cardiovasc Diabetol 16(1):22. https:\/\/doi.org\/10.1186\/s12933-017-0507-9","journal-title":"Cardiovasc Diabetol"},{"key":"6299_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2840-7-9","volume":"7","author":"X Yang","year":"2008","unstructured":"Yang X, Ma RC, So WY et al (2008) Development and validation of a risk score for hospitalization for heart failure in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 7:9. https:\/\/doi.org\/10.1186\/1475-2840-7-9","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06299-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:35:04Z","timestamp":1736868904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06299-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6299"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06299-x","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors thank all the participants and investigators of the HKDB for their contributions, and the medical and nursing staff of the diabetes centres involved for their professional input and support. Some of the data were presented as an abstract at the ADA's 83rd Scientific Sessions in 2023.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The datasets used during the current study are available from the corresponding author (RCWM) upon reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The measurement of NT-proBNP in the Hong Kong Diabetes Biobank was supported by an investigator-initiated grant from Roche Diagnostics (Hong Kong) Limited (to RCWM). Additional support for the Hong Kong Diabetes Biobank and this project came from the Research Grants Council of the Hong Kong Special Administrative Region (CU R4012-18), the Research Grants Council Theme-based Research Scheme (T12-402\/13N), the Focused Innovation Scheme, the University Research Grants Matching Scheme and a Croucher Foundation Senior Medical Research Fellowship. The funding sources did not have any role in the design, interpretation of the study results, or the decision to publish the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JCNC received consultancy fees or speaker honoraria from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Celltrion, Eli Lilly, Hua Medicine, Lee Power Pharmaceuticals, Merck, MSD, Pfizer, Roche, Sanofi, Servier, Viatris Pharmaceutical and Zuellig Pharma. JCNC is the Chief Executive Officer (pro bono) of the Asian Diabetes Foundation. APSK received consultancy fees, speaker honoraria and\/or research grants from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Kyowa Kirin, Merck Serono, Merck Sharp & Dohme, Nestle, Novo Nordisk, Pfizer, Sanofi and Zuellig Pharma. EC received speaker fees from Sanofi and Novartis, and institutional research funding from Sanofi, Medtronic Diabetes and Powder Pharmaceuticals, Inc. RCWM received research funding from AstraZeneca, Bayer, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Roche Diagnostics and Tricida, Inc. for carrying out clinical trials or studies, and from AstraZeneca, Bayer, Boehringer Ingelheim and Merck for speaker honoraria or consultancy in advisory boards. All proceeds have been donated to the Chinese University of Hong Kong to support diabetes research. RCWM is a member of the Editorial Board of\n                      Diabetologia\n                      . The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' relationships and activities"}},{"value":"Funding acquisition and overall project support were provided by RCWM. Conception and design of the work was provided by RCWM and CKPL. RCWM, YH, ESHL, RO, ACWN, AOYL, WYS, CKPL and JCNC were responsible for data collection and project logistics. RCWM, CHTT, YH, ESHL, JNML, EC, APSK, CH, EGF, ACWN and CKPL conducted the data analysis or data interpretation. RCWM and CHTT drafted the manuscript. RCWM, CHTT, YH, ESHL, RO, JNML, EC, APSK, CH, ACWN, EGF, AOYL, WYS, CKPL and JCNC provided critical revisions and contributed to the writing of the manuscript. All authors approved the final version of the article to be published. RCWM is responsible for the integrity of the work as a whole.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}